Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045455 | 0.96 | ALDH1A1 (0.41) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL27052880 | 0.94 | MEN1 (0.38) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL12500466 | 0.86 | MEN1 (0.34) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL14538819 | 0.86 | EPHX1 (0.49) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL18349839 | 0.85 | EPHX1 (0.36) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL14538977 | 0.84 | EPHX1 (0.47) | MEN1KMT2AEPHX1ALDH1A1POLB | |
| SCHEMBL6766479 | 0.84 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27052622 | 0.83 | EPHX1 (0.44) | EPHX1SMN1; SMN2 | |
| SCHEMBL27097854 | 0.83 | EPHX1 (0.44) | EPHX1SMN1; SMN2 | |
| SCHEMBL27055720 | 0.83 | EPHX1 (0.44) | EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945750-A2 | MICROARRAY HAVING A BASE CLEAVABLE SUCINATE LINKER | Combimatrix Corporation (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | claimed |
| WO-2007035500-A2 | MICROARRAY HAVING A BASE CLEAVABLE SUCCINATE LINKER | COMBIMATRIX CORPORATION (US) | 2007-03-29 | — | — | WO | claimed |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4547871-B1 | A METHOD, USES, SYSTEM AND KIT FOR DETECTING A HUMAN PAPILLOMAVIRUS GENOTYPE ASSOCIATED WITH DEVELOPMENT OF CERVICAL, ORAL OR ANOGENITAL CANCER IN A SUBJECT AND FOR DETERMINING THE GENOTYPE OR GENOTYPES THEREOF | VITRO S A (ES) | 2026-01-14 | — | — | EP | disclosed |
| US-20260002224-A1 | A METHOD, USES, SYSTEM AND KIT FOR DETECTING A HUMAN PAPILLOMAVIRUS GENOTYPE ASSOCIATED WITH DEVELOPMENT OF CERVICAL, ORAL OR ANOGENITAL CANCER IN A SUBJECT AND FOR DETERMINING THE GENOTYPE OR GENOTYPES THEREOF | VITRO, S.A. (ES) | 2026-01-01 | — | — | US | disclosed |
| US-20250361399-A1 | FLUORESCENT DYES WITH LARGE STOKES SHIFT | ROCHE MOLECULAR SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250325675-A1 | APTAMER, CONJUGATE, COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250320488-A1 | METHODS OF PREPARING OLIGONUCLEOTIDE-DIRECTED COMBINATORIAL LIBRARIES | INSITRO, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-20250269040-A1 | CONJUGATE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, METHOD FOR PREPARING SAME, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2025-08-28 | — | — | US | disclosed |
| US-6228592-B1 | MONITORING TARGET NUCLEOTIDE SEQUENCES IN SAMPLE; INSERT PROBES INTO SOLUTION, ALLOW HYBRIDIZATION TO OCCUR, MONITOR ADJUSTMENT IN FLUORESCENCE, ADJUSTMENT IN FLUORESCENCE INDICATES PRESENCE OF NUCLEIC ACIDS | LABORATORY OF MOLECULAR BIOPHOTONICS (JP) | 2001-05-08 | — | — | US | disclosed |
| US-6180347-B1 | DETECTING ACTIVATION AND TERMINATION OF TRANSCRIPTION; TRANSCRIBE SEQUENCES USING OLIGONUCLEOTIDE PROBES, MEASURING FLUORESCENCE OF PROBES AND EVALUATING ADJUSTMENT IN FLUORESCENCE | LABORATORY OF MOLECULAR BIOPHOTONICS (JP) | 2001-01-30 | — | — | US | disclosed |
| US-6172208-B1 | DIAGNOSTIC PROBE; DNA, RNA, PEPTIDE, AND PROTEIN CONJUGATES; GENETIC ENGINEERING | GENZYME CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-1052293-A1 | Nucleic acid detection in cytoplasm | Laboratory of Molecular Biophotonics (JP) | 2000-11-15 | — | — | EP | disclosed |
| EP-0965635-A1 | METHOD FOR MONITORING TRANSCRIPTIONAL SYNTHESIS OF RNA AND APPARATUS THEREFOR | Laboratory of Molecular Biophotonics (JP) | 1999-12-22 | — | — | EP | disclosed |
| US-6004826-A | Repair-mediated process for amplifying and detecting nucleic acid sequences | Segev, David | 1999-12-21 | — | — | US | disclosed |
| WO-1995019449-A1 | POPULATIONS OF NON-ADJACENT HYBRIDIZATION PROBES | APROGENEX, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995019450-A1 | BACKGROUND-REDUCING COMPOUNDS FOR PROBE-MEDIATED IN-SITU FLUORIMETRIC ASSAYS | APROGENEX, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1994001448-A1 | OLIGONUCLEOTIDES MODIFIED WITH CONJUGATE GROUPS | PHARMAGENICS, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | MEN1 1761/4885KMT2A 1710/4885EPHX1 2111/4885 |
| US-20250325675-A1 | APTAMER, CONJUGATE, COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | MCTS1, RNASE1, ASGR1 | MEN1 265/4885KMT2A 2008/4885EPHX1 2779/4885 |
| US-20260002224-A1 | A METHOD, USES, SYSTEM AND KIT FOR DETECTING A HUMAN PAPILLOMAVIRUS GENOTYPE ASSOCIATED WITH DEVELOPMENT OF CERVICAL, ORAL OR ANOGENITAL CANCER IN A SUBJECT AND FOR DETERMINING THE GENOTYPE OR GENOTYPES THEREOF | TSG101, MKI67, DHX35 | MEN1 3252/4885KMT2A 2259/4885EPHX1 250/4885 |
| US-20250269040-A1 | CONJUGATE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, METHOD FOR PREPARING SAME, AND USE THEREOF | RNASE1, MCTS1, ATIC | MEN1 221/4885KMT2A 1437/4885EPHX1 2812/4885 |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | MEN1 2986/4885KMT2A 3602/4885EPHX1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.